Phase 1/2 Study of the Safety and Efficacy of Rociletinib in Combination With Trametinib in Patients With mEGFR-positive Advanced or Metastatic Non-small Cell Lung Cancer

Part of paid clinical trials in St Louis, Missouri.

Sponsor
Clovis Oncology, Inc.
Study ID
NCT02580708
Phase
PHASE1/PHASE2
Status
Terminated

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

The purpose of this study is to evaluate the safety and anti-tumor effect of rociletinib when administered in combination with trametinib.

Key Dates

Start date
Sep 30, 2015
Status verified
Sep 2018
Primary completion
May 5, 2016
Completion
Jun 27, 2016

Study Design

Enrollment
7 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Rociletinib and Trametinib

Primary Outcome Measure

Incidence of treatment-emergent adverse events [ Time Frame: Continuously, up to approximately 24 months ]

Locations (4)

FacilityCityStateZIPSite coordinators
Washington University School of MedicineSt LouisMissouri63110-
Levine Cancer InstituteCharlotteNorth Carolina28204-
Tennessee Oncology, PLLC - The Sarah Cannon Research InstituteNashvilleTennessee37203-
Virginia Cancer SpecialistsFairfaxVirginia22031-

Find similar trials in St Louis, MO

By condition
Lung cancer
By specialty
OncologyLung oncologyLung disease
By research site
Washington University School of Medicine· St Louis, MOLevine Cancer Institute· Charlotte, NCTennessee Oncology, PLLC - The Sarah Cannon Research Institute· Nashville, TNVirginia Cancer Specialists· Fairfax, VA

Related Studies